SAKK 96/12 - Prevention of symptomatic skeletal complications with denosumab administered every 4 weeks versus every 12 weeks

The active ingredient in the drug Xgeva® (denosumab) is a so-called antibody. It is a protein with a similar structure to that produced by our own immune system during infections. This protein specifically inhibits the maturation and activity of bone-degrading cells (osteoclasts) and thus protects the bone from destruction by the tumor. This protein is digested in the body and does not burden the kidneys or liver. Results from several clinical studies indicate that administering Xgeva® every 12 weeks is as effective as administering Xgeva® every 4 weeks (standard treatment). Therefore, with this study we would like to test whether injecting Xgeva® every 12 weeks is as effective as administering it every 4 weeks. In addition to efficacy, side effects will also be closely monitored. We would like to check whether side effects occur less frequently as a result of the reduced administration of Xgeva®.

(BASEC)